Axogen Inc (AXGN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Axogen Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Axogen Inc 's ROA in the second quarter of 2026?
Axogen Inc recorded a cumulative net loss of $-34 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -13%.
However, within the Healthcare sector 320 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3315, from total ROA ranking in the first quarter of 2026 at 3617.
Axogen Inc, a global leader in surgical solutions for peripheral nerve injuries, recently reported an inducement grant made under NASDAQ listing rule 5635(c)(4) in connection with the hiring of a new non-executive employee. This news comes at a time when the company recorded a cumulative net loss of $24 million and experienced a decline in its return on assets within the healthcare sector. In this article, we will outline the facts surrounding these events and assess their impact on Axogen Inc. Fact 1: Inducement Grant for New Non-Executive Employee On July 1, 2024, Axogen Inc announced an inducement grant made under NASDAQ listing rule 5635(c)(4) for a new non-executive employee. This grant signifies the company s effort in attracting and retaining talented professionals to further its innovative surgical solutions within the peripheral nerve injuries sector.
Alachua, Fla. and Tampa, Fla., May 16, 2024 - Axogen Inc. (NASDAQ: AXGN), a recognized global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, is proud to announce the commencement of the rolling submission process for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for licensure of Avance Nerve Graft. This significant milestone was achieved on May 15, 2024. Avance Nerve Graft, Axogen s pioneering surgical solution, has demonstrated immense potential in addressing peripheral nerve injuries. With the initiation of the BLA submission process, Axogen is taking a crucial step towards making this revolutionary treatment available to patients in need.
Axogen Announces Leadership Transition as CEO Karen Zaderej Retires from Company in January 2025 ALACHUA and TAMPA, Fla., Jan. 4, 2024 - Axogen, Inc. (NASDAQ: AXGN), a pioneering force in developing and marketing groundbreaking surgical solutions for peripheral nerve injuries, has revealed its plan for a leadership transition, with President and CEO Karen Zaderej expected to retire from the company by January 2025. This strategic decision marks a significant turning point in Axogen s journey, as it paves the way for a new leader to guide the company towards continued innovation and growth. The organization s Board of Directors has taken a proactive approach to ensure a smooth transition by initiating the recruitment of a new CEO through an executive recruitment firm. Ms. Zaderej, while continuing to lead the company until a successor is appointed, will eventually step down from her role and her Board duties. However, she will remain connected to Axogen in a consultative capacity for an additional nine months, lending her expertise and support during the leadership transition process and the submission of the Biologics License Application (BLA) for the revolutionary Avanceâ„¢ Nerve Graft.
Axogen, Inc. Announces Inducement Grants for New VP of Finance and Investor Relations Amidst Cumulative Net Loss In a recent announcement, Axogen, Inc. (NASDAQ: AXGN), a renowned global player in the field of innovative surgical solutions for peripheral nerve injuries, revealed their decision to make Inducement Grants under NASDAQ Listing Rule 5635(c)(4). These grants are in connection with the appointment of Harold D. Tamayo as the Vice President of Finance and Investor Relations. This move is aimed at fortifying Axogen s financial capabilities and optimizing investor relations. Mr. Tamayo, who will report to Peter J. Mariani, the Executive Vice President and Chief Financial Officer, will be entrusted with the pivotal responsibilities of Financial Planning and Analysis as well as Investor Relations. However, the announcement comes at a time when Axogen Inc s financial performance shows troubling signs. As per reports, the company has recorded a cumulative net loss of a staggering $23 million during the 12-month period ending in the third quarter of 2023. This unfortunate situation has resulted in a negative return on assets (ROA) of -12.7%, raising concerns among investors and industry observers alike.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
